Related Experiment Video
Updated: Jan 8, 2026
Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia
Published on: October 17, 2025
Hyper-CVAD in Adults With Acute Lymphoblastic Leukemia in Ecuador: A Multicenter Retrospective Study
Brenner Sabando1, Jairo Quinonez1, Andrés Orquera2
1Department of Hematology, IRHED Medical Specialties Center, Guayaquil, Ecuador.
Background:
The Hyper-CVAD protocol is a chemotherapy regimen widely used in hematological malignancies. It is considered one of most promising remission-leading treatment option for adults with acute lymphoblastic leukemia (ALL).
Objective:
To determine the outcomes of adults with ALL treated with the Hyper-CVAD protocol in Ecuador.
Methods:
This multicenter, retrospective, cross-sectional study compared the outcomes of ALL patients aged 15 years and older treated with hyper-CVAD protocol in 8 specialized centers.
Results:
139 patients with ALL treated with the Hyper-CVAD protocol were included. A total of 79 were female (56.8%) and the majority had a B-type phenotype 130 (93.5%). A complete response (CR) was achieved in 64.3%. Relapse was confirmed in 52.7% of those who obtained CR. Negative minimal residual disease (MRD) was achieved in 20% of patients. The median overall survival (OS) was 11 months (95% CI: 7.49-14.50) with a 5-year OS of 14.0%. A total of 12 (8.6%) deceased during induction phase.
Conclusion:
Adult patients treated with the Hyper-CVAD protocol in Ecuador achieve rates of CR, MRD, and OS lower than those presented in international cohorts, as well as higher rates of treatment-related toxicity.
More Related Videos
10:49Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
Published on: September 18, 2013
06:08Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model
Published on: February 10, 2023
